Separate terms with OR to return results that match either term.
 
Clear All

716 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan. 1, 2016 In Use
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct. 1, 2010 June 30, 2011 No Longer Used
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 July 1, 2011 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan. 1, 2017 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 April 1, 2016 In Use
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan. 1, 2000 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan. 1, 2003 In Use
J8499 Immunotherapy - non specific Prescription drug, oral, non chemotherapeutic, nos NA Immunotherapy Yes Jan. 1, 1995 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan. 1, 2002 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No April 1, 2002 In Use
Q5113 Trastuzumab-pkrb Herzuma 10mg Immunotherapy Monoclonal Antibody HER2 No 2018 July 1, 2019 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 July 1, 2019 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 July 1, 2019 In Use
J9030 Bacillus calmette-guerin BCG Vaccine, Tice BCG 1mg Immunotherapy Biological Response Modifier Live Vaccine No 1990 July 1, 2019 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 July 1, 2019 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct. 1, 2019 In Use
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct. 1, 2019 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct. 1, 2019 In Use
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct. 1, 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct. 1, 2019 In Use

Found 716 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.